Sichuan Biokin's Subsidiary to Invest $5 Million in Oncology Drug Developer Connexus Therapeutics

Stock News

Yesterday

Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) has announced that its wholly-owned subsidiary, Pangu Capital, plans to subscribe for 3.881 million Series A preferred shares of Connexus Therapeutics for $5 million. Upon completion of this capital increase, the company will hold a 7.91% equity stake in Connexus.

Connexus is an innovative drug developer focused on the discovery of small-molecule therapeutics for oncology, with all of its pipeline candidates currently in preclinical development stages. The transaction is designed to make Connexus an associate company of Sichuan Biokin, thereby broadening the company's footprint in frontier technology areas beyond its existing platforms, including the innovative ADC drug development platform (HIRE-ADC), the innovative multispecific antibody platform (GNC), the specific enhanced bispecific antibody platform (SEBA), and the innovative ARC radiopharmaceutical development platform (HIRE-ARC), while supplementing its overall technology matrix.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/1154236776"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154236776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1154236776?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 19:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154236776","market":"fut","top_or_hot":-1,"title":"Sichuan Biokin's Subsidiary to Invest $5 Million in Oncology Drug Developer Connexus Therapeutics","media":"Stock News","content":"<p><b>Sichuan Biokin Pharmaceutical Co., Ltd.</b> (<b>688506.SH</b>) has announced that its wholly-owned subsidiary, Pangu Capital, plans to subscribe for 3.881 million Series A preferred shares of Connexus Therapeutics for $5 million. Upon completion of this capital increase, the company will hold a 7.91% equity stake in Connexus.<br><br>\nConnexus is an innovative drug developer focused on the discovery of small-molecule therapeutics for oncology, with all of its pipeline candidates currently in preclinical development stages. The transaction is designed to make Connexus an associate company of Sichuan Biokin, thereby broadening the company's footprint in frontier technology areas beyond its existing platforms, including the innovative ADC drug development platform (HIRE-ADC), the innovative multispecific antibody platform (GNC), the specific enhanced bispecific antibody platform (SEBA), and the innovative ARC radiopharmaceutical development platform (HIRE-ARC), while supplementing its overall technology matrix.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Biokin's Subsidiary to Invest $5 Million in Oncology Drug Developer Connexus Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Biokin's Subsidiary to Invest $5 Million in Oncology Drug Developer Connexus Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-17 19:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Sichuan Biokin Pharmaceutical Co., Ltd.</b> (<b>688506.SH</b>) has announced that its wholly-owned subsidiary, Pangu Capital, plans to subscribe for 3.881 million Series A preferred shares of Connexus Therapeutics for $5 million. Upon completion of this capital increase, the company will hold a 7.91% equity stake in Connexus.<br><br>\nConnexus is an innovative drug developer focused on the discovery of small-molecule therapeutics for oncology, with all of its pipeline candidates currently in preclinical development stages. The transaction is designed to make Connexus an associate company of Sichuan Biokin, thereby broadening the company's footprint in frontier technology areas beyond its existing platforms, including the innovative ADC drug development platform (HIRE-ADC), the innovative multispecific antibody platform (GNC), the specific enhanced bispecific antibody platform (SEBA), and the innovative ARC radiopharmaceutical development platform (HIRE-ARC), while supplementing its overall technology matrix.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"","article_id":"1154236776","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154236776","pubTimestamp":1789646181,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) has announced that its wholly-owned subsidiary, Pangu Capital, plans to subscribe for 3.881 million Series A preferred shares of Connexus...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"91194":"临工重机股份有限公司（临时代码）","159992":"创新药","688506":"百利天恒","LENZ":"Therapeutics","BK1574":"生物医药B类股","BK4139":"生物科技","BK4539":"次新股","06978":"永泰生物-B","BK0239":"医药制造","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK4007":"制药","LNGR":"Global X Longevity Thematic ETF","MEDX":"HORIZON KINETICS MEDICAL ETF","BK1161":"生物科技"},"translate_title":"四川Biokin子公司将向肿瘤药物开发商Connexus Therapeutics投资500万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91194":1,"159992":1,"688506":1,"IBBQ":1,"MEDX":1,"LNGR":1,"LENZ":1,"06978":1},"content_text":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) has announced that its wholly-owned subsidiary, Pangu Capital, plans to subscribe for 3.881 million Series A preferred shares of Connexus Therapeutics for $5 million. Upon completion of this capital increase, the company will hold a 7.91% equity stake in Connexus.\nConnexus is an innovative drug developer focused on the discovery of small-molecule therapeutics for oncology, with all of its pipeline candidates currently in preclinical development stages. The transaction is designed to make Connexus an associate company of Sichuan Biokin, thereby broadening the company's footprint in frontier technology areas beyond its existing platforms, including the innovative ADC drug development platform (HIRE-ADC), the innovative multispecific antibody platform (GNC), the specific enhanced bispecific antibody platform (SEBA), and the innovative ARC radiopharmaceutical development platform (HIRE-ARC), while supplementing its overall technology matrix.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}